Green Cross
Green Cross is an exemplary R&D-oriented company that leads the biotechnology
industry in Korea. This is clear given what Green Cross has achieved since
its foundation in 1967. Starting from the nation's first production and sales
of Plasma Fractions in 1970, which required sophisticated technology, Green
Cross has striven to develop ethical drugs that are hard to produce but
essential to patients. Subsequently, it is now an internationally recognized
biotechnology company in the fields of plasma fractions and vaccine.
Twelve years of research efforts have resulted in the world's third
development of a Hepatitis B vaccine in 1983. "Hepavax", a Hepatitis B
vaccine developed by Green Cross contributed to the health of the nation
substantially, by reducing by half the Hepatitis B virus carrier rate that
had reached 13%. Up to now, 400 million doses of"Hepavax", a quantity that
can vaccinate 130 million people, have been distributed to 60 countries and
international organizations such as WHO and UNICEF. It is recorded as the
most widely used Hepatitis B vaccine.